VivoSeq
Other

Infertility

97

Pipeline Programs

24

Active Trials

34

Companies Involved

Infertility is a moderately active landscape with 97 programs across 34 companies. The most active players are Sclnow Biotechnology Co., Ltd., Azurity Pharmaceuticals, Eastern Cooperative Oncology Group. 38 therapies are approved with 23 more in late-stage development.

Pipeline Metrics

Competitive Density

70/100

Pipeline Velocity

37/100

Mech. Concentration

9/100

Completion Rate

76/100

Attrition Rate

9/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

96%

Small molecule

105 of 109 classified programs — the dominant modality here.

4%ALL OTHERSCell therapy22%Protein / enzyme1<1%Peptide1<1%

Small molecule leads; the ring shows all 109 classified programs, each share of the total. Modality classified for 97% of 122 pipeline programs.

Trial Status

86

clinical trials

Completed31 · 36%
Unknown status21 · 24%
Recruiting14 · 16%
Not yet recruiting6 · 7%
Terminated5 · 6%
Withdrawn3 · 3%
Other6 · 7%

Trial Activity

86 trials

Uterus Transplantation to Treat Infertility
Recruiting·JJohns Hopkins University·Phase 2/3·NCT05646992·40 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)